HLB "US Subsidiary Verismo Introduces KIR-CAR Mechanism"

HLB announced on the 14th that its U.S. subsidiary Verismo presented the clinical design (STAR-101) related to the next-generation chimeric antigen receptor (CAR)-T therapy platform 'KIR-CAR' in the form of a poster at the Bile Duct Cancer Foundation Annual Meeting held in Utah, USA.

Verismo Therapeutics logo. [Photo by Verismo Therapeutics]

원본보기 아이콘

The Bile Duct Cancer Foundation was established in 2006 in Salt Lake City, Utah, USA, and holds an annual meeting every year. At this year's 10th meeting, specialists in bile duct cancer and industry stakeholders gather to present and discuss the latest research papers and innovative treatments related to bile duct cancer.

The research results presented under the title "Phase 1 Clinical Trial of KIR-CAR for Patients with Bile Duct Cancer, Mesothelioma, and Ovarian Cancer" include the mechanism of action showing how the next-generation CAR-T drug candidate 'SynKIR-110' recognizes and eliminates cancers when administered to patients with bile duct cancer, mesothelioma, and ovarian cancer that overexpress mesothelin.

Through this Phase 1 clinical trial, Verismo plans to confirm the efficacy, safety, optimal dosage, clinical response rate, and biomarkers of SynKIR-110.

SynKIR-110 is designed by linking a mesothelin-specific antibody to NK cell signaling, enabling the patient's T cells to easily recognize and attack cancer cells. The company explained that by applying technology that expresses a multichain receptor similar to the receptor structure of NK immune cells on T cells, it overcomes the limitations of existing CAR-T therapies, which are confined to blood cancer treatment, and is effective against various solid tumors.

Laura Johnson, CSO of Verismo, said, "We are pleased to introduce the key design and outcomes related to the ongoing Phase 1 trial at this conference," adding, "We will do our best to provide new treatment options to patients suffering from intractable cancers through rapid clinical development."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.